Inovio Pharmaceuticals, Inc.

As of November 9, 2023, Inovio Pharmaceuticals, Inc. is considered overvalued with a valuation grade change to "does not qualify," marked by a Price to Book Value of 1.62, negative EV to EBIT and EV to EBITDA ratios, and a Return on Equity of -204.32%, alongside a troubling long-term performance decline of 99.25% over five years.

As of June 17, 2025, Inovio Pharmaceuticals, Inc. is in a mildly bearish trend, influenced by daily moving averages and monthly Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST, indicating a cautious market environment.

As of March 2022, the management team of Inovio Pharmaceuticals, Inc. includes Mr. Simon Benito (Independent Chairman), Dr. Jong Kim (CEO), Dr. David Weiner, Dr. Ann Miller, Mr. Jay Shepard, Ms. Wendy Yarno, and Ms. Lota Zoth (all Independent Directors). They oversee the company's strategic direction and operations.

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing DNA immunotherapies and vaccines for cancer and infectious diseases. As of March 2025, it has a market cap of $69.68 million, with net sales of $0 and a net loss of $20 million.

As of Jun 18, Inovio Pharmaceuticals, Inc. has a market capitalization of 69.68 million, with net sales of 0.29 million and a net profit of -96.48 million over the latest four quarters. Shareholder's funds are reported at 68.50 million, and total assets amount to 114.90 million.